Patents by Inventor Johan W. Stjernschantz

Johan W. Stjernschantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5627208
    Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 6, 1997
    Assignee: Pharmacia Aktiebolag
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5578618
    Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: November 26, 1996
    Assignee: Pharmacia Aktiebolag
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
    Patent number: 5516796
    Abstract: Thiosubstituted prostaglandin derivatives and related compounds having the general structure ##STR1## useful as intraocular pressure reducing agents; pharmaceutical compositions containing such compounds; and methods of treatment using such compositions are disclosed.
    Type: Grant
    Filed: March 24, 1994
    Date of Patent: May 14, 1996
    Assignee: Kabi Pharmacia AB
    Inventors: Johan W. Stjernschantz, Bahram Resul, Laszlo Z. Bito
  • Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5422368
    Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: June 6, 1995
    Assignee: Kabi Pharmacia AB
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Prostaglanddin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5422369
    Abstract: This invention relates a method for topical treatment of glaucoma or ocular hypertension by administration of an effective intraocular pressure reducing amont of a prostaglandin derivative of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure. The invention further relates to compositions comprising said prostaglandin derivatives in an ophthalmologically compatible carrier.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: June 6, 1995
    Assignee: Kabi Pharmacia AB
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5321128
    Abstract: This invention relates a method for topical treatment of glaucoma or ocular hypertension by administration of an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure. The invention further relates to compositions comprising said prostaglandin derivatives in an ophthalmologically compatible carrier.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: June 14, 1994
    Assignee: Kabi Pharmacia AB
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5296504
    Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: March 22, 1994
    Assignee: Kabi Pharmacia
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
    Patent number: 5114971
    Abstract: 11-epi PGF.sub.2 alpha esters are employed in treating glaucoma or ocular hypertension.
    Type: Grant
    Filed: October 23, 1990
    Date of Patent: May 19, 1992
    Assignee: Kabi Pharmacia AB
    Inventors: Johan W. Stjernschantz, Bahram Resul
  • Composition for the topical treatment of glaucoma or ocular hypertension
    Patent number: 5079253
    Abstract: A method for the topical treatment of glaucoma or ocular hypertension which comprises contacting the surface of the eye with a composition consisting essentially of an effective intraocular pressure reducing amount of a mixture of (a) an adrenergic agonist selected from the group consisting of epinephrine, dipivalylepinephrine, norepinephrine, phenylephrine, clonidine, isoproterenol, salbutamol, metaproterenol and terbutaline, and (b) a phosphodiesterase inhibitor selected from the group consisting of isobutylmethylxanthine, theophyllamine, Rolipram and RO-2017624, in an ophthalmically compatible carrier.
    Type: Grant
    Filed: November 22, 1988
    Date of Patent: January 7, 1992
    Assignee: Pharmacia AB
    Inventors: Philip Hoyng, Johan W. Stjernschantz
  • Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
    Patent number: 4952581
    Abstract: This invention provides a method for treating ocular hypertension or glaucoma in a subject's eye. The method comprises contacting the surface of the eye with an effective intraocular pressure reducing amount of a mixture of an adrenergic blocking agent and a prostaglandin or prostaglandin derivative in an ophthalmically compatible carrier, so as to reduce the intraocular pressure of the eye and maintain such reduced intraocular pressure.This invention also provides a composition for topical treatment of ocular hypertension or glaucoma in the eye of a subject. The composition comprises an effective intraocular pressure reducing amount of a mixture of an adrenergic block agent and a prostaglandin or prostaglandin derivative in an ophthalmically compatible carrier.
    Type: Grant
    Filed: December 30, 1988
    Date of Patent: August 28, 1990
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Laszlo Z. Bito, Johan W. Stjernschantz